Illimis Therapeutics

Raised $42M in a Series B round, announced 14 July 2025.

Total raised: $42M

Latest round Series BCountry South KoreaSector Health

Round

$42MSeries B, 14 July 2025

Funds GAIA-based Alzheimer's therapeutics and expansion into immune disorders.

Amount: $42M
Stage: Series B
Announced: 14 July 2025
Lead: DSC Investment
Other investors: Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, Dayli Partners
Use of funds: Funds GAIA-based Alzheimer's therapeutics and expansion into immune disorders.
Checked: Announced by the company
Sources: Illimis Therapeutics raises 58 billion KRW (~$42M) biospace.com
Illimis Therapeutics raises 58 billion KRW (~$42M) pulse2.com

Company

Drugs for CNS and immune diseases built on its GAIA platform, led by Alzheimer's

Based in: South Korea
Sector: Health

Questions

How much has Illimis Therapeutics raised?

Illimis Therapeutics raised $42M in a Series B round, announced on 14 July 2025.

Who invested in Illimis Therapeutics?

DSC Investment led. Investors include DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management and Company K Partners.